What is the current name for polycystic ovary syndrome (PCOS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PCOS Is Now Called Polyendocrine Metabolic Ovarian Syndrome (PMOS)

The condition formerly known as polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) as of 2026, following a rigorous global consensus process involving 56 international organizations and input from over 14,000 patients and healthcare professionals 1.

Why the Name Changed

The term "polycystic ovary syndrome" was fundamentally inaccurate and misleading for nearly 90 years. The characteristic ovarian appearance reflects numerous arrested antral follicles, not pathological cysts 2. This misnomer created several critical problems:

  • Delayed diagnosis in up to 70% of affected individuals by focusing attention narrowly on ovarian morphology 3
  • Obscured the multisystem nature of the condition, which involves endocrine, metabolic, psychological, and cardiovascular features 1
  • Contributed to stigma and fragmented care by implying a purely reproductive disorder 1
  • Limited research funding and policy attention by misrepresenting the condition's scope 1

What PMOS Means

The new name accurately captures three core pathophysiological domains:

  • Polyendocrine: Reflects hyperandrogenism, disrupted gonadotropin secretion, and neuroendocrine dysregulation 1
  • Metabolic: Centers insulin resistance (affecting 75% of lean and 95% of overweight women), dysglycemia, dyslipidemia, and cardiovascular risk 4
  • Ovarian: Acknowledges ovulatory dysfunction and characteristic ovarian morphology without the misleading "cysts" terminology 1

Diagnostic Criteria Remain Unchanged

The Rotterdam criteria still apply: diagnosis requires 2 of 3 features:

  • Irregular menstrual cycles/ovulatory dysfunction
  • Clinical or biochemical hyperandrogenism
  • Elevated anti-Müllerian hormone or polycystic ovarian morphology on ultrasound 2

These criteria are outlined in the 2013 Endocrine Society guideline 5 and reaffirmed in the 2018 International Evidence-Based Guideline.

Clinical Implications of the Rename

The shift from PCOS to PMOS represents a fundamental reframing from a fertility-centered view to recognition as a lifelong cardiometabolic condition:

  • Cardiovascular risk diverges from age 35, with 1.2-2.5-fold increased risk of major adverse cardiovascular events 4
  • Nearly 3-fold increased risk of type 2 diabetes (OR 2.9) 4
  • Pregnancy complications including gestational diabetes, preeclampsia, preterm birth, and fetal growth restriction persist even after adjusting for BMI 2

Common pitfall: PMOS is still not routinely documented as an obstetric risk modifier at first prenatal visits, leading to missed opportunities for enhanced surveillance and prevention 2.

Implementation Strategy

A coordinated global transition is underway with:

  • Gradual evolution rather than abrupt transformation to minimize disruption 1
  • Alignment with ICD coding systems and health records 3
  • Education campaigns for clinicians and patients 6
  • Transition period allowing both terms temporarily while PMOS becomes standard 1

This parallels successful nomenclature updates like the shift from NAFLD to metabolic dysfunction-associated steatotic liver disease (MASLD) 3.

What Hasn't Changed

  • Diagnostic criteria remain identical 2
  • Treatment approaches continue to follow evidence-based guidelines 5, 7
  • The existing research base and evidence remain fully applicable 6

The rename corrects historical inaccuracy while preserving clinical continuity, enabling more accurate diagnosis, broader multidisciplinary care, and reduced stigma for the one in eight women affected by this condition 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.